🚀 VC round data is live in beta, check it out!
Avadel Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Avadel Pharmaceuticals and similar public comparables like Yifan Pharmaceutical, Mabwell, BioCryst Pharma, Nippon Shinyaku and more.
Avadel Pharmaceuticals Overview
About Avadel Pharmaceuticals
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Founded
2015
HQ
Employees
188
Website
Sectors
Financials (LTM)
EV
$2B
Avadel Pharmaceuticals Financials
Avadel Pharmaceuticals reported last 12-month revenue of $292M and EBITDA of $40M.
In the same LTM period, Avadel Pharmaceuticals generated $272M in gross profit, $40M in EBITDA, and $24M in net income.
Revenue (LTM)
Avadel Pharmaceuticals P&L
In the most recent fiscal year, Avadel Pharmaceuticals reported revenue of — and net income of —.
Avadel Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $292M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $272M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | — | XXX | XXX | XXX |
| EBITDA | $40M | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | — | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | — | XXX | XXX | XXX |
| Net Profit | $24M | XXX | — | XXX | XXX | XXX |
| Net Margin | 8% | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Avadel Pharmaceuticals Stock Performance
Avadel Pharmaceuticals has current market cap of $2B, and enterprise value of $2B.
Avadel Pharmaceuticals' stock price is $21.64.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -0.1% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAvadel Pharmaceuticals Valuation Multiples
Avadel Pharmaceuticals trades at 7.0x EV/Revenue multiple, and 51.4x EV/EBITDA.
Avadel Pharmaceuticals Financial Valuation Multiples
As of March 21, 2026, Avadel Pharmaceuticals has market cap of $2B and EV of $2B.
Equity research analysts estimate Avadel Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Avadel Pharmaceuticals has a P/E ratio of 86.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 7.0x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | 51.4x | XXX | — | XXX | XXX | XXX |
| EV/EBIT | 50.0x | XXX | — | XXX | XXX | XXX |
| EV/Gross Profit | 7.5x | XXX | — | XXX | XXX | XXX |
| P/E | 86.9x | XXX | — | XXX | XXX | XXX |
| EV/FCF | 29.8x | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Avadel Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Avadel Pharmaceuticals Margins & Growth Rates
Avadel Pharmaceuticals' revenue in the last 12 month grew by 23%.
Avadel Pharmaceuticals' revenue per employee in the last FY averaged $1.6M.
Avadel Pharmaceuticals' rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Avadel Pharmaceuticals' rule of X is 71% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Avadel Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | 63% | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 134% | XXX | (211%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 71% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.6M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Avadel Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Yifan Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Mabwell | XXX | XXX | XXX | XXX | XXX | XXX |
| BioCryst Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Nippon Shinyaku | XXX | XXX | XXX | XXX | XXX | XXX |
| Ultragenyx | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Avadel Pharmaceuticals M&A Activity
Avadel Pharmaceuticals acquired XXX companies to date.
Last acquisition by Avadel Pharmaceuticals was on XXXXXXXX, XXXXX. Avadel Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Avadel Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAvadel Pharmaceuticals Investment Activity
Avadel Pharmaceuticals invested in XXX companies to date.
Avadel Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Avadel Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Avadel Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Avadel Pharmaceuticals
| When was Avadel Pharmaceuticals founded? | Avadel Pharmaceuticals was founded in 2015. |
| Where is Avadel Pharmaceuticals headquartered? | Avadel Pharmaceuticals is headquartered in United States. |
| How many employees does Avadel Pharmaceuticals have? | As of today, Avadel Pharmaceuticals has over 188 employees. |
| Is Avadel Pharmaceuticals publicly listed? | Yes, Avadel Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Avadel Pharmaceuticals? | Avadel Pharmaceuticals trades under AVDL ticker. |
| When did Avadel Pharmaceuticals go public? | Avadel Pharmaceuticals went public in 1996. |
| Who are competitors of Avadel Pharmaceuticals? | Avadel Pharmaceuticals main competitors are Yifan Pharmaceutical, Mabwell, BioCryst Pharma, Nippon Shinyaku. |
| What is the current market cap of Avadel Pharmaceuticals? | Avadel Pharmaceuticals' current market cap is $2B. |
| What is the current revenue of Avadel Pharmaceuticals? | Avadel Pharmaceuticals' last 12 months revenue is $292M. |
| What is the current revenue growth of Avadel Pharmaceuticals? | Avadel Pharmaceuticals revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of Avadel Pharmaceuticals? | Current revenue multiple of Avadel Pharmaceuticals is 7.0x. |
| Is Avadel Pharmaceuticals profitable? | Yes, Avadel Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Avadel Pharmaceuticals? | Avadel Pharmaceuticals' last 12 months EBITDA is $40M. |
| What is Avadel Pharmaceuticals' EBITDA margin? | Avadel Pharmaceuticals' last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Avadel Pharmaceuticals? | Current EBITDA multiple of Avadel Pharmaceuticals is 51.4x. |
| What is the current FCF of Avadel Pharmaceuticals? | Avadel Pharmaceuticals' last 12 months FCF is $68M. |
| What is Avadel Pharmaceuticals' FCF margin? | Avadel Pharmaceuticals' last 12 months FCF margin is 23%. |
| What is the current EV/FCF multiple of Avadel Pharmaceuticals? | Current FCF multiple of Avadel Pharmaceuticals is 29.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.